Study Stopped
Trial was planned for 2020, but Melbourne 2020 and 2021 lockdowns hindered the study.
Nut Intake At Night: Effect on Postprandial Glycaemia
The Effect of Nut Intake At Night on Postprandial Glycaemia: a Randomised Crossover Trial in Healthy Adults
1 other identifier
interventional
N/A
0 countries
N/A
Brief Summary
There is some evidence to suggest that the timing of a meal intake directly impacts postprandial insulin and glucose responses, with meals consumed later during the day being more metabolically detrimental that the same meals consumed during the day. This information is particularly pertinent to the 16% of people employed in shift-work professions in Australia who have little choice but to eat during the late evening and overnight. The purpose of this study is to compare two effect of different meals or snacks (control vs test meal) on blood glucose and insulin at night time in healthy adults. This study will enable to develop suitable meals to consume at night time that can reduce the higher glucose and insulin responses that are a consequence of eating late into the night.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
Started Dec 2024
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 8, 2021
CompletedFirst Posted
Study publicly available on registry
July 16, 2021
CompletedStudy Start
First participant enrolled
December 1, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 30, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
October 30, 2025
CompletedNovember 22, 2024
November 1, 2024
8 months
July 8, 2021
November 19, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Postprandial plasma glucose area under the curve (iAUC)
Difference in postprandial plasma glucose iAUC
Three hour glucose iAUC will be calculated at nine time points (0, 15, 30, 45, 60, 90, 120, 150 and 180 mins) after beginning consumption of the test meal.
Postprandial plasma insulin iAUC
Difference in postprandial plasma insulin iAUC
Three hour glucose iAUC will be calculated at seven time points (0, 30, 60, 90, 120, 150 and 180 mins) after beginning consumption of the test meal.
Secondary Outcomes (3)
Postprandial glucose concentration
Glucose concentration will be measured at nine time points (0, 15, 30, 45, 60, 90, 120, 150 and 180 mins) after beginning consumption of the test meal.
Postprandial insulin concentration
Insulin concentration will be measured in finger prick blood samples at seven time points (0, 30, 60, 90, 120, 150 and 180 mins) after beginning consumption of the test meal.
Time to peak glucose
Three hours
Study Arms (2)
Control meal
PLACEBO COMPARATORParticipants will receive plain white rice (75g of available carbohydrate) alongside a snack with crackers and cheese. The meal is similar in energy and macronutrients to the test meal.
Nut meal
EXPERIMENTALParticipants will receive plain white rice (75g of available carbohydrate) alongside a portion of 30g of nuts. The meal is similar in energy and macronutrients to the control meal.
Interventions
Participants will receive plain white rice (75g of available carbohydrate) alongside a snack with crackers and cheese. The meal is similar in energy and macronutrients to the test meal.
Participants will receive plain white rice (75g of available carbohydrate) alongside a portion of 30g of nuts. The meal is similar in energy and macronutrients to the control meal.
Eligibility Criteria
You may qualify if:
- to 50 years of age
- Waist circumference of \<94cm and \<80cm for Caucasian males and females, respectively
- Waist circumference of \<90cm and \<80 cm for Asian males and females, respectively
- Available to attend two testing sessions at the research facility
You may not qualify if:
- Diagnosed with type 2 diabetes or taking anti-diabetic medication (oral hypoglycaemic agents)
- Impaired fasting glucose (≥ 7 mmol/L)
- Gastrointestinal conditions that may affect glycaemic response
- Serious health conditions that may affect participation e.g. liver or thyroid dysfunction, recent major surgery
- Women planning pregnancy, pregnant or lactating.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- OTHER
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Lecturer
Study Record Dates
First Submitted
July 8, 2021
First Posted
July 16, 2021
Study Start
December 1, 2024
Primary Completion
July 30, 2025
Study Completion
October 30, 2025
Last Updated
November 22, 2024
Record last verified: 2024-11
Data Sharing
- IPD Sharing
- Will not share